Glutamylvaline | 5879-06-1

• 物质功能分类: 生物化工 - 生化试剂 - 氨基酸
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Glutamylvaline
• 英文别名: 4-amino-5-[(1-carboxy-2-methylpropyl)amino]-5-oxopentanoic acid
• CAS: 5879-06-1
• 化学式: C₁₀H₁₈N₂O₅
• mdl: MFCD02029021
• 分子量: 246.26
• InChiKey: SITLTJHOQZFJGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.9
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  130
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• DIPEPTIDE-CONTAINING COMPOSITION FOR ORAL ADMINISTRATION
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1941896A1

  公开（公告）日：2008-07-09

  The present invention provides a composition for oral administration, which comprises at least one kind of dipeptide represented by the formula:         X-Y (wherein X represents alanyl, glycyl, arginyl, seryl, α-aspartyl or α-glutamyl, and Y represents valine, leucine or isoleucine), with an object of providing a composition for oral administration which is excellent in nutrition, pharmacological effect and gustation and comprises at least one kind selected from valine, leucine and isoleucine, or providing a composition for oral administration which is excellent in processing characteristics such as solubility and tableting property and comprises at least one kind selected from valine, leucine and isoleucine.

  本发明提供了一种口服组合物，它包含至少一种由式表示的二肽： X-Y (其中 X 代表丙氨酰、甘氨酰、精氨酰、丝氨酰、α-天冬氨酰或α-谷氨酰，Y 代表缬氨酸、亮氨酸或异亮氨酸），其目的是提供一种营养、药效和口感俱佳的口服组合物，该组合物至少包含一种选自缬氨酸、亮氨酸和异亮氨酸的二肽、或提供一种口服组合物，该组合物在加工特性（如溶解性和压片性能）方面非常出色，并包含至少一种选自缬氨酸、亮氨酸和异亮氨酸的成分。
• Biomarkers for fatty liver disease and methods using the same
  申请人：Metabolon Inc.

  公开号：EP2546649A2

  公开（公告）日：2013-01-16

  The present invention provides various biomarkers of fatty liver disease, including steatosis and steatohepatitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of fatty liver disease, methods of determining predisposition to fatty liver disease, methods of monitoring progression/regression of fatty liver disease, methods of assessing efficacy of compositions for treating fatty liver disease, methods of screening compositions for activity in modulating biomarkers of fatty liver disease, methods of treating fatty liver disease, as well as other methods based on biomarkers of fatty liver disease.

  本发明提供了脂肪肝的各种生物标志物，包括脂肪变性和脂肪性肝炎。本发明还提供了使用这些生物标志物的各种方法，包括诊断脂肪肝的方法、确定脂肪肝易感性的方法、监测脂肪肝进展/恶化的方法、评估治疗脂肪肝组合物疗效的方法、筛选组合物调节脂肪肝生物标志物活性的方法、治疗脂肪肝的方法以及基于脂肪肝生物标志物的其他方法。
• Method of assessing pancreatic beta-cell function
  申请人：Gall Walter

  公开号：US10302663B2

  公开（公告）日：2019-05-28

  Biomarkers relating to pancreatic Beta-cell function, pancreatic Beta-cell glucose sensitivity, insulin resistance, and/or pancreatic Beta-cell-related disorders are provided. Methods based on the same biomarkers are also provided.

  提供了与胰岛β细胞功能、胰岛β细胞葡萄糖敏感性、胰岛素抵抗和/或胰岛β细胞相关疾病有关的生物标志物。还提供了基于相同生物标志物的方法。
• Gastrointestinal tract detection methods, devices and systems
  申请人：Progenity Inc.

  公开号：US10610104B2

  公开（公告）日：2020-04-07

  The present disclosure relates to gastrointestinal (GI) tract detection methods, devices and systems.

  本公开涉及胃肠道（GI）检测方法、装置和系统。
• Ingestible device and associated methods
  申请人：Progenity Inc.

  公开号：US11224364B2

  公开（公告）日：2022-01-18

  An ingestible device is disclosed which can produce spectral data of one or more analytes, as well as associated methods for characterizing the gastrointestinal tract of a subject which contains such analytes. Related kits and systems are also disclosed.

  本研究公开了一种可摄取的装置，它可以产生一种或多种分析物的光谱数据，还公开了相关方法，用于描述含有这些分析物的受试者的胃肠道特征。还公开了相关的试剂盒和系统。